Document is current
Any future updates will be listed below
-
Authors
Franx, Bart A. A.
Arnoldussen, Ilse A. C.
Kiliaan, Amanda J.
Gustafson, Deborah R.
-
Funding
Funding for this research was provided by:
State University of New York - Downstate Medical Center institutional research funds
Swedish Research Council for Health, Working Life and Welfare, AGECAP (2013-2300, 2013-2496)
EFRO project (BriteN PROJ-00405)
National Institute of Allergy and Infectious Diseases (UO1-AI-35004, UO1-AI-31834, UO1-AI-34994, UO1-AI-34989, UO1-AI-34993, UO1-AI-42590)
- License Information
-
More Information
Article History
First Online: 6 May 2017
Compliance with Ethical Standards
:
: Support for this review is as follows: DR Gustafson, State University of New York, Downstate Medical Center institutional research funds and the Swedish Research Council for Health, Working Life and Welfare, AGECAP 2013-2300, 2013-2496; AA Franx, IC Arnoldussen, AJ Kiliaan AJ, EFRO project BriteN (PROJ-00405). The Women's Interagency HIV Study (WIHS), National Institute of Allergy and Infectious Diseases (UO1-AI-35004, UO1-AI-31834, UO1-AI-34994, UO1-AI-34989, UO1-AI-34993, and UO1-AI-42590).
: Bart A.A. Franx, Ilse A.C. Arnoldussen, Amanda J. Kiliaan, and Deborah R. Gustafson have no conflicts of interest directly relevant to the content of this article. No support was obtained specifically for writing or publishing this review. Dr. Kiliaan and Dr. Gustafson were Investigators in LipiDiDiet, a multicenter translational project funded by the European Commission (). Dr. Kiliaan performed animal experiments using Fortysyn Connect<sup>®</sup>. Dr. Gustafson analyzed epidemiological data on the association between dementia and adiposity, cardiovascular risk factors, and the APOE genotype. Neither Dr. Kiliaan nor Dr. Gustafson was directly involved in the clinical trial of Souvenaid<sup>®</sup> in patients with biomarker-based mild cognitive impairment.
